Related Experiment Video
Updated: Oct 19, 2025
Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
Published on: May 6, 2020
SPRY4 acts as an indicator of osteoarthritis severity and regulates chondrocyte hypertrophy and ECM protease
Sunghyun Park1,2, Yoshie Arai1, Alvin Bello3
1Department Medical Biotechnology, Dongguk University Biomedi Campus, Goyang-si, Gyeonggi-do, Republic of Korea.
Abstract:
Osteoarthritis (OA) causes serious changes in the metabolic and signaling pathways of chondrocytes, including the mitogen-activated protein kinase (MAPK) pathway. However, the role of sprouty RTK signaling antagonist 4 (SPRY4), an inhibitor of MAPK, in the human cartilage tissues and chondrocytes remains to be understood. Here, using SPRY4 gene delivery into healthy and degenerated chondrocytes, we elucidated the role of SPRY4 in preventing chondrocyte hypertrophy. In addition to using the human cartilage tissues with the destabilization of the medial meniscus (DMM) model in Sprague-Dawley (SD) rats, the role of SPRY4 in cartilage tissues and chondrocytes was explored through their molecular and histological analyses. In order to determine the effects of SPRY4 on healthy human chondrocyte hypertrophy, small interfering RNA (siRNA) was used to knock down SPRY4. Lentiviral transduction of SPRY4 into degenerated human chondrocytes allowed us to investigate its ability to prevent hypertrophy. SPRY4 expression levels were higher in healthy human cartilage tissue and chondrocytes than in degenerated human cartilage tissues and hypertrophy-induced chondrocytes. The knockdown of SPRY4 in healthy chondrocytes caused an increase in hypertrophy, senescence, reactive oxygen species (ROS) production, and extracellular matrix (ECM) protease expression. However, all these factors decreased upon overexpression of SPRY4 in degenerated chondrocytes via regulation of the MAPK signaling pathway. We conclude that SPRY4 is a crucial indicator of osteoarthritis (OA) severity and could play an important role in preventing OA in the cartilage by inhibiting chondrocyte hypertrophy.
Insights
Sprouty RTK signaling antagonist 4 (SPRY4) inhibits chondrocyte hypertrophy, a key factor in osteoarthritis (OA). Upregulating SPRY4 in degenerated cartilage may prevent OA progression by regulating the MAPK pathway.
Area of Science:
- Cell Biology
- Molecular Biology
- Biochemistry
Background:
- Osteoarthritis (OA) involves altered chondrocyte metabolism and signaling, notably the MAPK pathway.
- The specific role of SPRY4, a MAPK inhibitor, in human cartilage and chondrocytes is not fully understood.
Purpose of the Study:
- To investigate the role of SPRY4 in preventing chondrocyte hypertrophy in human cartilage.
- To explore SPRY4's potential as a therapeutic target for osteoarthritis.
Main Methods:
- Gene delivery of SPRY4 into healthy and degenerated human chondrocytes.
- Utilizing small interfering RNA (siRNA) to knock down SPRY4 in healthy chondrocytes.
- Employing the destabilization of the medial meniscus (DMM) rat model for in vivo analysis.
- Molecular and histological analyses of human cartilage tissues and chondrocytes.
Main Results:
- SPRY4 expression is higher in healthy human cartilage than in degenerated cartilage.
- SPRY4 knockdown in healthy chondrocytes increased hypertrophy, senescence, ROS, and ECM protease expression.
- SPRY4 overexpression in degenerated chondrocytes reduced these factors by regulating the MAPK pathway.
Conclusions:
- SPRY4 plays a critical role in inhibiting chondrocyte hypertrophy.
- SPRY4 is a potential indicator of OA severity.
- Modulating SPRY4 may offer a novel strategy for preventing osteoarthritis.
